Ask AI
Pier Luigi Zinzani

Pier Luigi Zinzani, MD, PhD

Professor of Hematology
Alma Mater Studiorum-University of Bologna
Head, “Seràgnoli” Institute of Hematology
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Department of Medical and Surgical Sciences
Bologna University School of Medicine
Bologna, Italy

Explore Activities by Pier Luigi Zinzani

Title
Format
Credit Type
Credits
Guida del paziente agli ultimi progressi clinici nelle nuove terapie per la leucemia linfatica cronica o il linfoma linfocitico piccolo recidivante/refrattario

Content Format:

PDF

Credit Type:

--

Credits:

--
Guida del paziente agli ultimi progressi clinici nelle nuove terapie per la leucemia linfatica cronica o il linfoma linfocitico piccolo recidivante/refrattario

Content Format:

PDF

Credit Type:

--

Credits:

--
Guida del paziente agli ultimi progressi clinici nelle nuove terapie per la leucemia linfatica cronica o il linfoma linfocitico piccolo recidivante/refrattario

Content Format:

PDF

Credit Type:

--

Credits:

--
Guida del paziente agli ultimi progressi clinici nelle nuove terapie per la leucemia linfatica cronica o il linfoma linfocitico piccolo recidivante/refrattario

Content Format:

PDF

Credit Type:

--

Credits:

--
Guida del paziente agli ultimi progressi clinici nelle nuove terapie per la leucemia linfatica cronica o il linfoma linfocitico piccolo recidivante/refrattario

Content Format:

PDF

Credit Type:

--

Credits:

--
Guida del paziente agli ultimi progressi clinici nelle nuove terapie per la leucemia linfatica cronica o il linfoma linfocitico piccolo recidivante/refrattario

Content Format:

PDF

Credit Type:

--

Credits:

--
BTK Degrader Bexobrutideg in Patients With Relapsed/Refractory CLL/SLL  

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
Second-line Pirtobrutinib in CLL/SLL After Covalent BTKi Treatment: A Pooled Analysis of BRUIN LOXO-BTK18001 and BRUIN CLL-321  

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
CaDAnCe-101 Phase I Study of the BTK Degrader BGB-16673 in R/R CLL/SLL  

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
BRUIN CLL-314: Pirtobrutinib vs Ibrutinib in Treatment-Naive and BTKi-Naive R/R CLL/SLL  

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
Final Analysis of the Phase I/II BRUIN Trial of Pirtobrutinib in Patients With CLL/SLL Previously Treated with a Covalent BTKi    

Content Format:

Conference Coverage

Credit Type:

AMA

Credits:

0.25
ALPINE Long-term Extension Study of Zanubrutinib in Relapsed or Refractory CLL/SLL

Content Format:

Conference Coverage

Credit Type:

AMA

Credits:

0.25
Congress to Clinic: Expert Perspectives on Therapeutic Advances and Practice Changing Data Emerging From the 2025 EHA and ICML Congresses

Content Format:

Text Module

Credit Type:

AMA

Credits:

1.00
Congress to Clinic: Expert Perspectives on Therapeutic Advances and Practice Changing Data Emerging From the 2025 EHA and ICML Congresses

Content Format:

Slideset

Credit Type:

--

Credits:

--
Evolving Paradigms in Hematologic Malignancies: Expert Insights on 6 Key Abstracts From EHA and ICML 2025

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Applying Data to Practice: BTK Inhibitor Therapies to Treat CLL and MCL

Content Format:

Video

Credit Type:

AMA

Credits:

1.00
2023 Global Conference Coverage Updates on BTK Inhibitors for CLL and MCL

Content Format:

Slideset

Credit Type:

--

Credits:

--